BridgeMD
TALAMESO : A Three-Cohort Phase II trial to Assess the Efficacy of a Maintenance Treatment with TALAzoparib following First Line Platinum-based Chemotherapy in Pleural or Malignant Peritoneal MESOthelioma Patients
EU CTIS ID: 2024-514104-14-00
What this study is testing
To assess the efficacy, assessed by the proportion of patients who are free of progression 6 months after starting talazoparib maintenance treatment, that will follow minimum 4 cycles of systemic platinum-based first line chemotherapy, in patients with advanced malignant pleural (cohort A) or peritoneal mesothelioma (cohorts B1 and B2).
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients older than 18 years old
- Patients with adequate hepatic function: o Total bilirubin ≤ 1.5 × upper limit of normal [ULN] o ASAT/ALAT ≤1.5 × ULN
- Patients must have a life expectancy ≥ 16 weeks.
- Confirmation of non-childbearing status (pregnancy test) for women of childbearing potential.
- A highly effective method of contraception is required for female patients during treatment of talazoparib, and for at least 7 months after completing therapy. Advise male patients with female partners of reproductive potential and pregnant partners to use a condom, during treatment with talazoparib and for at least 4 months after the final dose
- Patients who gave its written informed consent to participate to the study.
You likely can't join if
- Uncontrolled intercurrent illness, including but not limited to, such as congestive heart failure; respiratory distress; liver failure; allergy, or psychiatric illness/social situations that would limit compliance with study requirement according to the investigator, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
- Known HIV or AIDS related illness.
- Positive test for HBV surface antigen and / or confirmatory HCV RNA (if anti-HCV antibody tested positive).
- Treatment with oral anticoagulant anti-vitamin K such Coumadin®.
- Prior organ transplantation, including allogeneic stem cell transplantation (excluding autologous bone marrow transplant).
- Patients under guardianship.
See the full eligibility criteria
Who can join
- Patients older than 18 years old
- Patients with adequate hepatic function: o Total bilirubin ≤ 1.5 × upper limit of normal [ULN] o ASAT/ALAT ≤1.5 × ULN
- Patients must have a life expectancy ≥ 16 weeks.
- Confirmation of non-childbearing status (pregnancy test) for women of childbearing potential.
- A highly effective method of contraception is required for female patients during treatment of talazoparib, and for at least 7 months after completing therapy. Advise male patients with female partners of reproductive potential and pregnant partners to use a condom, during treatment with talazoparib and for at least 4 months after the final dose
- Patients who gave its written informed consent to participate to the study.
- Patients affiliated to a social insurance regime.
- Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
- Patients with Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- Histologically - or cytologically- confirmed malignant mesotheliomas: epithelioid, sarcomatoid, biphasic - Developed from pleura (cohort A) or from peritoneum (cohorts B1 and B2) - Previously treated with systemic platinum based-chemotherapy (including minimum one cycle of pemetrexed) for minimum 4 cycles, with no sign of disease progression during chemotherapy
- No previous treatment with bevacizumab and PARP inhibitor
- Minimum 6 weeks and maximum 8 weeks interval between last chemotherapy cycle and talazoparib start OR minimum 6 and maximum 8 weeks after cytoreductive surgery performed after neo-adjuvant treatment (including the necessary number of cycles of platinum-pemetrexed for inclusion) in the absence of adjuvant chemotherapy. - For pleural mesotheliomas (cohort A), primary or interval debulking surgery with or without hyperthermic intrapleural or intrathoracic chemotherapy (HITHOC) will be authorized, in the case of non-complete cytoreductive surgery only - For peritoneal mesotheliomas * In cohort B1, primary or interval debulking surgery ± hyperthermic intraperitoneal chemotherapy (HIPEC) will be authorized in the case of non-complete cytoreductive surgery (CC2 or CC3) only. This cohort will also include patients with non-operated diseases. Intraperitoneal treatments with pressurized intraperitoneal aerosol chemotherapy sessions (PIPAC) are allowed only with systemic chemotherapy for this cohort. * In cohort B2, complete macroscopic (CC0 or CC1) primary or interval debulking surgery ± HIPEC will be required. Intraperitoneal treatments with pressurized intraperitoneal aerosol chemotherapy sessions (PIPAC) are allowed in neoadjuvant chemotherapy treatment prior to surgery. **In all cohorts, HITHOC, HIPEC and PIPAC are NOT considered as systemic platinum-based chemotherapy
- Measurable or non-measurable (but radiologically evaluable) disease as per modified RECIST version 1.1 on computed tomography (CT) scan (within 28 days prior to talazoparib initiation), or for cohort B2, authorization of absence of radiological lesion
- Availability at the study site of a representative Formalin-Fixed Paraffin-Embedded (FFPE) tumor sample in a block if possible or at least 30 unstained slides from biopsy or surgery specimen, aged less than 18 months.
- Patients with adequate bone marrow function measured within 28 days prior to administration of study treatment as defined below: o Absolute neutrophil count ≥1.0 x 109 /L o Platelet count ≥50 x 109 /L o Haemoglobin ≥8.0 g/dL (may have been blood transfused)
- Patients with adequate renal function: o Calculated Glomerular Filtration Rate ≥30 ml/min/1.73 m2 according to CKD-EPI formula
What rules you out
- Uncontrolled intercurrent illness, including but not limited to, such as congestive heart failure; respiratory distress; liver failure; allergy, or psychiatric illness/social situations that would limit compliance with study requirement according to the investigator, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
- Known HIV or AIDS related illness.
- Positive test for HBV surface antigen and / or confirmatory HCV RNA (if anti-HCV antibody tested positive).
- Treatment with oral anticoagulant anti-vitamin K such Coumadin®.
- Prior organ transplantation, including allogeneic stem cell transplantation (excluding autologous bone marrow transplant).
- Patients under guardianship.
- Women who are breastfeeding (during treatment with talazoparib and for at least 1 month after the final dose).
- Participation in other interventional clinical research that may interfere with the experimental drugs efficacy.
- In cohorts B1 and B2: Patients with tumor recurrence within 9 months of the last cycle of previous platinum-based chemotherapy line
- Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≥ 5 years.
- All subjects with brain metastases or meningeal involvement.
- Patients receiving any systemic chemotherapy, radiotherapy (except for palliative reasons), within 6 weeks from the last dose prior to study treatment (or a longer period depending on the defined characteristics of the agents used). The patient can receive a stable dose of bisphosphonates for bone metastases, before and during the study as long as these were started at least 4 weeks prior to treatment with study drug.
- Persistent toxicities (CTCAE ≥ grade 2) with the exception of alopecia and sensory neuropathy, caused by previous cancer therapy.
- Treatment with other investigational agents.
- Bowel occlusive syndrome, inflammatory bowel disease, immune colitis, or other gastro-intestinal disorder that does not allow oral medication such as malabsorption.
- Known severe hypersensitivity reactions to PARP inhibitors.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.